Castle Biosciences, Inc.
US ˙ NasdaqGM ˙ US14843C1053

SecurityCSTL / Castle Biosciences, Inc.
InstitutionDimensional Fund Advisors Lp
Latest Disclosed Ownership1,143,799 shares
Ownership 3.90%
Dimensional Fund Advisors Lp ownership in CSTL / Castle Biosciences, Inc.

2026-01-21 - Dimensional Fund Advisors Lp has filed an SCHEDULE 13G/A form with the Securities and Exchange Commission (SEC) disclosing ownership of 1,143,799 shares of Castle Biosciences, Inc. (US:CSTL). This represents 3.9 percent ownership of the company. In their previous filing dated 2025-10-09 , Dimensional Fund Advisors Lp had reported owning 1,474,089 shares, indicating a decrease of -22.41 percent.

Institutional Ownership: 13D/G Filings

This table shows a history of the 13D/G filings made by the investor and/or investor group. Note that the share values in this table are not directly comparable to any numbers shown in the 13F table (if any).

File
Date
Effective
Date
Form Prev
Shares
Latest
Shares
ΔShares
(Percent)
Ownership
(Percent)
ΔOwnership
(Percent)
2026-01-21 2026-01-21 13G/A 1,474,089 1,143,799 -22.41 3.90 -23.53
2025-10-09 2025-10-09 13G 1,474,089 5.10

Important Note: One of the primary uses of the 13D/G filings is to evaluate the ability of a firm to control a company (ie, the "beneficial ownership"). To that end, firms are required to report not just direct holdings in companies, but indirect holdings that they control. For investment firms, these indirect holdings can include shares in funds they manage, advisory accounts, and in the case of activist campaigns, pledged votes. Therefore, share counts listed in 13D/G filings can differ significantly than share counts listed in 13F filings.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date
Effective
Date
Form Security Class ID Avg Price
Paid (Est)
Reported
Shares
ΔShares ΔShares
(%)
Reported
Value
(x1000)
ΔValue
(%)
Alloc
(%)
ΔAlloc ΔAlloc (%) Cost Basis
(x1000)
Unrealized
Gain/Loss
(x1000)
2026-05-07 2026-03-31 13F CASTLE BIOSCIENCES COM 14843C105 1,039,761 -104,038 -9.10 25,523 -42.64 0.0011
2026-02-12 2025-12-31 13F CASTLE BIOSCIENCES COM 14843C105 1,143,799 -330,290 -22.41 44,495 32.56 0.0093
2025-11-12 2025-09-30 13F CASTLE BIOSCIENCES COM 14843C105 1,474,089 96,084 6.97 33,564 19.28 0.0072
2025-08-12 2025-06-30 13F CASTLE BIOSCIENCES COM 14843C105 1,378,005 177,783 14.81 28,139 17.11 0.0065
2025-05-13 2025-03-31 13F CASTLE BIOSCIENCES COM 14843C105 1,200,222 200,756 20.09 24,028 -9.79 0.0060
2025-02-13 2024-12-31 13F CASTLE BIOSCIENCES COM 14843C105 999,466 134,645 15.57 26,636 8.00 0.0064
2024-11-07 2024-09-30 13F CASTLE BIOSCIENCES COM 14843C105 864,821 54,887 6.78 24,663 39.89 0.0060
2024-08-09 2024-06-30 13F CASTLE BIOSCIENCES COM 14843C105 809,934 60,675 8.10 17,631 6.23 0.0046
2024-05-10 2024-03-31 13F CASTLE BIOSCIENCES COM 14843C105 749,259 85,377 12.86 16,596 15.84 0.0045
2024-02-07 2023-12-31 13F CASTLE BIOSCIENCES COM 14843C105 663,882 108,481 19.53 14,328 52.72 0.0042
2023-11-09 2023-09-30 13F CASTLE BIOSCIENCES COM 14843C105 555,401 65,818 13.44 9,381 39.68 0.0031
2023-08-09 2023-06-30 13F CASTLE BIOSCIENCES COM 14843C105 489,583 5,931 1.23 6,717 -38.87 0.0021
2023-05-12 2023-03-31 13F CASTLE BIOSCIENCES COM 14843C105 483,652 159,966 49.42 10,988 156,857.14 0.0037
2023-02-09 2022-12-31 13F CASTLE BIOSCIENCES COM 14843C105 323,686 85,198 35.72 8 -99.89 0.0023
2022-11-10 2022-09-30 13F CASTLE BIOSCIENCES COM 14843C105 238,488 46,410 24.16 6,220 47.50 0.0024
2022-08-12 2022-06-30 13F CASTLE BIOSCIENCES COM 14843C105 192,078 69,700 56.95 4,217 -23.17 0.0015
2022-05-13 2022-03-31 13F CASTLE BIOSCIENCES COM 14843C105 122,378 8,278 7.26 5,489 12.20 0.0017
2022-02-09 2021-12-31 13F CASTLE BIOSCIENCES COM 14843C105 114,100 59,783 110.06 4,892 35.44 0.0015
2021-11-12 2021-09-30 13F CASTLE BIOSCIENCES COM 14843C105 54,317 54,317 3,612 0.0012
2021-08-12 2021-06-30 13F CASTLE BIOSCIENCES COM 14843C105 0 -142,988 -100.00 0 -100.00
2021-05-14 2021-03-31 13F CASTLE BIOSCIENCES COM 14843C105 142,988 122,306 591.36 9,755 602.30 0.0032
2021-03-08 2020-12-31 13F/A-2 CASTLE BIOSCIENCES COM 14843C105 20,682 20,682 1,389 0.0005
2021-02-11 2020-12-31 13F CASTLE BIOSCIENCES COM 14843C105 20,682 20,682 1,389 0.0005
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.